Feutren G, von Graffenried B
Sandoz Pharma LTD, Basle.
Schweiz Med Wochenschr. 1991 May 18;121(20):748-53.
Pilot studies with cyclosporin A (CsA, Sandimmun) in more than 100 patients with Crohn's disease have shown that CsA was more efficient in chronic active disease than in acute attacks. The onset of effect was rapid, usually within the first month, but most patients relapsed during the weeks following the interruption of CsA treatment. These findings were confirmed by a placebo-controlled study (parallel groups) in 71 patients, in whom the rate of improvement at 3 months was 61% on CsA and 33% on placebo. Promising results have also been reported after short-term use of intravenous CsA in severe acute ulcerative colitis. Further controlled trials are still ongoing in order to ascertain the efficacy of CsA administered according to the current safety guidelines (dose less than or equal to 5 mg/kg/day) for a period of one year in patients with chronic active Crohn's disease.
对100多名克罗恩病患者进行的环孢素A（CsA，山地明）试点研究表明，CsA在慢性活动性疾病中比在急性发作中更有效。起效迅速，通常在第一个月内，但大多数患者在CsA治疗中断后的几周内复发。一项针对71名患者的安慰剂对照研究（平行组）证实了这些发现，其中服用CsA的患者在3个月时的改善率为61%，服用安慰剂的患者为33%。在严重急性溃疡性结肠炎中短期静脉使用CsA后也报告了有前景的结果。目前仍在进行进一步的对照试验，以确定按照当前安全指南（剂量小于或等于5mg/kg/天）给药一年的CsA对慢性活动性克罗恩病患者的疗效。
